Research
Hormonal
Using semaglutide is associated with successful weight reduction at the follow-up of 6 months (OR = 2.138).
Semaglutide may be a more effective option for weight reduction in patients treated with GLP-1RA.
StrongSupportsmedium confidence
Non-diabetic status (OR = 2.176, 95% CI, 1.242-3.812) and using semaglutide (OR = 2.138, 95% CI, 1.162-3.935) were associated with successful weight reduction at the follow-up of 6 months.
Why this rating
Based on a retrospective cohort study with a substantial sample size.
Source
Glucagon‐like peptide‐1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity
Jingxuan Wang et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16552
cohort · n=679Cited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →